• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

经股动脉途径行冠状动脉介入治疗患者大出血预后风险评分的建立与验证

Development and validation of a prognostic risk score for major bleeding in patients undergoing percutaneous coronary intervention via the femoral approach.

作者信息

Nikolsky Eugenia, Mehran Roxana, Dangas George, Fahy Martin, Na Yingbo, Pocock Stuart J, Lincoff A Michael, Stone Gregg W

机构信息

Cardiovascular Research Foundation, Columbia University Medical Center, Herbert Irving Pavilion, 5th Floor, 161 Fort Washington Avenue, New York, NY 10032, USA.

出版信息

Eur Heart J. 2007 Aug;28(16):1936-45. doi: 10.1093/eurheartj/ehm194. Epub 2007 Jun 15.

DOI:10.1093/eurheartj/ehm194
PMID:17575270
Abstract

AIMS

Major bleeding after percutaneous coronary intervention (PCI) is an independent risk factor for early and late mortality. We developed and validated a risk score predictive of major bleeding after PCI using the femoral approach.

METHODS AND RESULTS

Baseline clinical and procedural variables from two contemporary, multicentre, randomized PCI trials were used for risk score development (the REPLACE-2 trial, n = 6002) and validation (the REPLACE-1 trial, n = 1056). On the basis of the odds ratio, independent risk factors were assigned a weighted integer, the sum of which comprised a total risk score. Seven variables were identified as independent correlates of major bleeding (age >55 years, female gender, estimated glomerular filtration rate <60 mL/min/1.73 m(2), pre-existing anaemia, administration of low-molecular-weight heparin within 48 h pre-PCI, use of glycoprotein IIb/IIIa inhibitors, and intraaortic balloon pump use). In the development set, the risk of major bleeding varied from 1.0% in patients without risk factors to 5.4% in high-risk patients. The discriminatory power of this risk model was confirmed in the validation data set (area under the receiver operating curve = 0.62).

CONCLUSION

A simple risk score of baseline clinical and procedural variables is useful to predict the incidence of major peri-procedural bleeding after contemporary PCI using the femoral approach.

摘要

目的

经皮冠状动脉介入治疗(PCI)后发生的大出血是早期和晚期死亡的独立危险因素。我们开发并验证了一种使用股动脉入路预测PCI后大出血的风险评分。

方法与结果

来自两项当代多中心随机PCI试验的基线临床和手术变量用于风险评分的开发(REPLACE-2试验,n = 6002)和验证(REPLACE-1试验,n = 1056)。基于优势比,为独立危险因素分配一个加权整数,其总和构成总风险评分。七个变量被确定为大出血的独立相关因素(年龄>55岁、女性、估计肾小球滤过率<60 mL/min/1.73 m²、既往贫血、PCI术前48小时内使用低分子量肝素、使用糖蛋白IIb/IIIa抑制剂以及使用主动脉内球囊泵)。在开发组中,大出血风险在无危险因素的患者中为1.0%,在高危患者中为5.4%。该风险模型的辨别能力在验证数据集中得到证实(受试者工作特征曲线下面积 = 0.62)。

结论

一个基于基线临床和手术变量的简单风险评分有助于预测当代使用股动脉入路的PCI围手术期大出血的发生率。

相似文献

1
Development and validation of a prognostic risk score for major bleeding in patients undergoing percutaneous coronary intervention via the femoral approach.经股动脉途径行冠状动脉介入治疗患者大出血预后风险评分的建立与验证
Eur Heart J. 2007 Aug;28(16):1936-45. doi: 10.1093/eurheartj/ehm194. Epub 2007 Jun 15.
2
Major bleeding complicating contemporary primary percutaneous coronary interventions-incidence, predictors, and prognostic implications.当代直接经皮冠状动脉介入治疗相关的严重出血——发生率、预测因素及预后影响
Cardiovasc Revasc Med. 2009 Apr-Jun;10(2):88-93. doi: 10.1016/j.carrev.2008.08.001.
3
Incremental Value of Platelet Reactivity Over a Risk Score of Clinical and Procedural Variables in Predicting Bleeding After Percutaneous Coronary Intervention via the Femoral Approach: Development and Validation of a New Bleeding Risk Score.经股动脉途径行经皮冠状动脉介入治疗后,血小板反应性相对于临床和手术变量风险评分在预测出血方面的增量价值:一种新的出血风险评分的开发与验证
Circ Cardiovasc Interv. 2015 May;8(5). doi: 10.1161/CIRCINTERVENTIONS.114.002106.
4
Incidence, predictors, and clinical impact of bleeding after transradial coronary stenting and maximal antiplatelet therapy.经桡动脉冠状动脉支架置入术及最大程度抗血小板治疗后出血的发生率、预测因素及临床影响。
Am Heart J. 2009 Jan;157(1):164-9. doi: 10.1016/j.ahj.2008.09.010. Epub 2008 Nov 6.
5
Body mass index, periprocedural bleeding, and outcome following percutaneous coronary intervention (from the British Columbia Cardiac Registry).体重指数、围手术期出血与经皮冠状动脉介入治疗后的结局(来自不列颠哥伦比亚心脏注册中心)
Am J Cardiol. 2009 Feb 15;103(4):507-11. doi: 10.1016/j.amjcard.2008.10.027.
6
Predicting major adverse cardiac events after percutaneous coronary intervention: the Texas Heart Institute risk score.经皮冠状动脉介入治疗后主要不良心脏事件的预测:德州心脏研究所风险评分
Am Heart J. 2008 Jun;155(6):1068-74. doi: 10.1016/j.ahj.2008.01.034. Epub 2008 Apr 3.
7
Development and validation of a bleeding risk model for patients undergoing elective percutaneous coronary intervention.择期经皮冠状动脉介入治疗患者出血风险模型的建立与验证。
Int J Cardiol. 2011 Jul 1;150(1):79-83. doi: 10.1016/j.ijcard.2010.02.077. Epub 2010 Mar 17.
8
Risk factors for the development of retroperitoneal hematoma after percutaneous coronary intervention in the era of glycoprotein IIb/IIIa inhibitors and vascular closure devices.在糖蛋白IIb/IIIa抑制剂和血管闭合装置时代,经皮冠状动脉介入治疗后发生腹膜后血肿的危险因素。
J Am Coll Cardiol. 2005 Feb 1;45(3):363-8. doi: 10.1016/j.jacc.2004.10.042.
9
Incidence, predictors, and prognostic implications of hospitalization for late bleeding after percutaneous coronary intervention for patients older than 65 years.> 对于 65 岁以上接受经皮冠状动脉介入治疗的患者,晚期出血住院的发生率、预测因素及预后意义。
Circ Cardiovasc Interv. 2010 Apr;3(2):140-7. doi: 10.1161/CIRCINTERVENTIONS.109.928721. Epub 2010 Mar 23.
10
Impact of nephropathy after percutaneous coronary intervention and a method for risk stratification.经皮冠状动脉介入治疗后肾病的影响及风险分层方法
Am J Cardiol. 2004 Jun 15;93(12):1515-9. doi: 10.1016/j.amjcard.2004.03.008.

引用本文的文献

1
Antithrombotic drugs for acute coronary syndromes in women: sex-adjusted treatment and female representation in randomised clinical trials. A clinical consensus statement of the European Association of Percutaneous Cardiovascular Interventions (EAPCI) and the ESC Working Group on Thrombosis.女性急性冠状动脉综合征的抗血栓药物:性别调整治疗及随机临床试验中的女性代表性。欧洲经皮心血管介入协会(EAPCI)和欧洲心脏病学会血栓形成工作组的临床共识声明。
EuroIntervention. 2025 Jun 16;21(12):e655-e667. doi: 10.4244/EIJ-D-24-00876.
2
Tailoring Antithrombotic Regimens for Percutaneous Coronary Intervention Patients with High Bleeding and Ischemic Risk (): Individualized Management and Genotype-Guided De-escalation.为具有高出血和缺血风险的经皮冠状动脉介入治疗患者量身定制抗血栓治疗方案( ):个体化管理与基因分型指导的降阶梯治疗
Rev Cardiovasc Med. 2023 Dec 12;24(12):348. doi: 10.31083/j.rcm2412348. eCollection 2023 Dec.
3
Guidelines on optimizing the use of proton pump inhibitors: PPI stewardship.质子泵抑制剂优化使用指南:PPI 管理。
Indian J Gastroenterol. 2023 Oct;42(5):601-628. doi: 10.1007/s12664-023-01428-7. Epub 2023 Sep 12.
4
Impact of anemia on major bleeding in patients taking oral anticoagulants for nonvalvular atrial fibrillation.贫血对非瓣膜性心房颤动患者口服抗凝剂治疗时严重出血的影响。
J Arrhythm. 2023 Jun 16;39(4):556-565. doi: 10.1002/joa3.12885. eCollection 2023 Aug.
5
The Management and Antithrombotic Strategies of Patients with Coronary Artery Disease and High Bleeding Risk.《冠心病合并高出血风险患者的管理与抗栓策略》
Curr Cardiol Rep. 2023 Jul;25(7):669-680. doi: 10.1007/s11886-023-01893-8. Epub 2023 Jun 7.
6
Sex Differences in Baseline Characteristics Do Not Predict Early Outcomes after Percutaneous Coronary Intervention: Results from the Australian GenesisCare Cardiovascular Outcomes Registry (GCOR).经皮冠状动脉介入治疗后基线特征的性别差异不能预测早期结局:来自澳大利亚创世纪医疗心血管结局登记处(GCOR)的结果。
J Clin Med. 2022 Feb 21;11(4):1138. doi: 10.3390/jcm11041138.
7
The safety and efficacy of haemostasis with a catechol-conjugated, chitosan-based haemostatic dressing versus a chitosan-based haemostatic dressing after transfemoral approach for transcatheter arterial chemoembolization: a randomized controlled trial.经股动脉途径进行经导管动脉化疗栓塞术后,使用儿茶酚共轭壳聚糖基止血敷料与壳聚糖基止血敷料止血的安全性和有效性:一项随机对照试验。
Pol J Radiol. 2021 Dec 29;86:e685-e691. doi: 10.5114/pjr.2021.112327. eCollection 2021.
8
Direct Oral Anticoagulants Combined with Antiplatelet Therapy in the Treatment of Coronary Heart Disease: An Updated Meta-analysis.直接口服抗凝剂联合抗血小板治疗在冠心病治疗中的应用:一项更新的荟萃分析。
Drugs. 2021 Nov;81(17):2003-2016. doi: 10.1007/s40265-021-01637-4. Epub 2021 Nov 3.
9
Acute Anemia and Myocardial Infarction.急性贫血与心肌梗死
Cureus. 2021 Aug 11;13(8):e17096. doi: 10.7759/cureus.17096. eCollection 2021 Aug.
10
Analysis of Immune Associated Co-Expression Networks Reveals Immune-Related Long Non-Coding RNAs during MI in the Presence and Absence of HDC.免疫相关共表达网络分析揭示了 HDC 存在和不存在时 MI 过程中的免疫相关长非编码 RNA。
Int J Mol Sci. 2021 Jul 9;22(14):7401. doi: 10.3390/ijms22147401.